Trial reportPloS one2013
Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.
Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 60 citations in OpenAlex.
- Intrathecal morphine administration reduces postoperative pain and peripheral endocannabinoid levels in total knee arthroplasty patients: a randomized clinical trial.BMC anesthesiology · 2018Trial
- Interspecies differences in the expression of cannabinoid receptors at the tissue and cellular levels.Neural regeneration research · 2026Article
- Functional Foods and Nutraceuticals in Irritable Bowel Syndrome.Journal of clinical medicine · 2025Review
- The Endocannabinoid System: Implications in Gastrointestinal Physiology and Pathology.International journal of molecular sciences · 2025Review
- Endocannabinoid system modulation for visceral abdominal pain in inflammatory bowel disease and irritable bowel syndrome: A protocol for systematic review and meta-analysis.HRB open research · 2025Article
- Therapeutic Potential of Palmitoylethanolamide in Gastrointestinal Disorders.Antioxidants (Basel, Switzerland) · 2024Review
- The Endocannabinoid System and Physical Exercise.International journal of molecular sciences · 2023Review
- Economic living standard and abdominal pain mediate the association between functional gastrointestinal disorders and depression or anxiety.Neurogastroenterology and motility · 2023Article
- The Enteric Glia and Its Modulation by the Endocannabinoid System, a New Target for Cannabinoid-Based Nutraceuticals?Molecules (Basel, Switzerland) · 2022Review
- Palmitoylethanolamide and Related ALIAmides for Small Animal Health: State of the Art.Biomolecules · 2022Review
- Differential mRNA expression in ileal and colonic biopsies in irritable bowel syndrome with diarrhea or constipation.American journal of physiology. Gastrointestinal and liver physiology · 2022Article
- Serum Concentrations of the Endocannabinoid, 2-Arachidonoylglycerol, in the Peri-Trauma Period Are Positively Associated with Chronic Pain Months Later.Biomedicines · 2022Article
- Oral Adelmidrol Administration Up-Regulates Palmitoylethanolamide Production in Mice Colon and Duodenum through a PPAR-γ Independent Action.Metabolites · 2022Article
- Metabolomics: The Key to Unraveling the Role of the Microbiome in Visceral Pain Neurotransmission.Frontiers in neuroscience · 2022Review
- Circulating Endocannabinoids as Diagnostic Markers of Canine Chronic Enteropathies: A Pilot Study.Frontiers in veterinary science · 2021Article
- Relevance of Sex and Subtype in Patients With IBS: An Exploratory Study of Gene Expression.Biological research for nursing · 2020Article
- Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment.Frontiers in neuroscience · 2020Article
- µ-opioid receptor, β-endorphin, and cannabinoid receptor-2 are increased in the colonic mucosa of irritable bowel syndrome patients.Neurogastroenterology and motility · 2019Article
- Endocannabinoid-related compounds in gastrointestinal diseases.Journal of cellular and molecular medicine · 2018Review
- Quality of life and depression in patients with irritable bowel syndrome.Przeglad gastroenterologiczny · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsIrritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder, associated with alterations of bowel function, abdominal pain and other symptoms related to the GI tract. Recently the endogenous cannabinoid system (ECS) was shown to be involved in the physiological and pathophysiological control of the GI function. The aim of this pilot study was to investigate whether IBS defining symptoms correlate with changes in endocannabinoids or cannabinoid like fatty acid levels in IBS patients.
methodsAEA, 2-AG, OEA and PEA plasma levels were determined in diarrhoea-predominant (IBS-D) and constipation-predominant (IBS-C) patients and were compared to healthy subjects, following the establishment of correlations between biolipid contents and disease symptoms. FAAH mRNA levels were evaluated in colonic biopsies from IBS-D and IBS-C patients and matched controls.
resultsPatients with IBS-D had higher levels of 2AG and lower levels of OEA and PEA. In contrast, patients with IBS-C had higher levels of OEA. Multivariate analysis found that lower PEA levels are associated with cramping abdominal pain. FAAH mRNA levels were lower in patients with IBS-C.
conclusionIBS subtypes and their symptoms show distinct alterations of endocannabinoid and endocannabinoid-like fatty acid levels. These changes may partially result from reduced FAAH expression. The here reported changes support the notion that the ECS is involved in the pathophysiology of IBS and the development of IBS symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.